Deutsche Bank’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-25,078
| Closed | -$1.89M | – | 4150 |
|
|
2022
Q2 | $1.89M | Sell |
25,078
-56,603
| -69% | -$2.52M | ﹤0.01% | 1797 |
|
|
2022
Q1 | $2.19M | Buy |
81,681
+93
| +0.1% | +$3.13K | ﹤0.01% | 1832 |
|
|
2021
Q4 | $3.89M | Sell |
81,588
-7,278
| -8% | -$325K | ﹤0.01% | 1588 |
|
|
2021
Q3 | $5.9M | Buy |
88,866
+7,997
| +10% | +$570K | ﹤0.01% | 1409 |
|
|
2021
Q2 | $6.31M | Buy |
80,869
+24,897
| +44% | +$1.84M | ﹤0.01% | 1397 |
|
|
2021
Q1 | $5.29M | Sell |
55,972
-3,070
| -5% | -$365K | ﹤0.01% | 1515 |
|
|
2020
Q4 | $7.2M | Buy |
59,042
+32,493
| +122% | +$3.56M | ﹤0.01% | 1176 |
|
|
2020
Q3 | $2.32M | Sell |
26,549
-3,343
| -11% | -$233K | ﹤0.01% | 1655 |
|
|
2020
Q2 | $1.93M | Buy |
29,892
+10,799
| +57% | +$623K | ﹤0.01% | 1812 |
|
|
2020
Q1 | $853K | Buy |
19,093
+4,588
| +32% | +$244K | ﹤0.01% | 2183 |
|
|
2019
Q4 | $901K | Buy |
14,505
+12,440
| +602% | +$592K | ﹤0.01% | 2433 |
|
|
2019
Q3 | $75K | Sell |
2,065
-6,320
| -75% | -$275K | ﹤0.01% | 3716 |
|
|
2019
Q2 | $339K | Buy |
+8,385
| New | +$299K | ﹤0.01% | 3521 |
|
Deutsche Bank's TPTX Position: Q3 2022 in Review
Deutsche Bank sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 25,078 shares — an estimated $1.89M sold.
Deutsche Bank first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $7.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Deutsche Bank reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Deutsche Bank sold 25,078 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.89M.
- Deutsche Bank first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Deutsche Bank's Turning Point Therapeutics, Inc. Common Stock position peaked at $7.2M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Deutsche Bank's 13F filing for Q3 2022, filed 14 Nov 2022.